CEPI—a new global R&D organisation for epidemic preparedness and response

Abstract

Effi cacy and safety of albendazole plus ivermectin, albendazole plus mebendazole, albendazole plus oxantel pamoate, and mebendazole alone against Trichuris trichiura and concomitant soil-transmitted helminth infections: a four-arm, randomised controlled trial. Lancet Infect Dis 2015; 15: 277-84. 9 Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefi ts, many concerns for the next generation evidence synthesis tool.

Nucleoside analogues for the treatment of coronavirus infections

“…Notably, no vaccines or antiviral compounds are approved for prevention or treatment of human or potential zoonotic CoVs. Emerging CoVs have been accorded priority status by WHO and government agencies for development of prevention and treatment strategies due to severity of these infections and credible pandemic potential [7][8][9]. This review will focus on opportunities for and challenges to development of antiviral nucleoside and nucleotide analogues targeting viral RNA synthesis as effective therapeutics against CoV infections.…”

Diagnostic preparedness for infectious disease outbreaks

“…We propose to set up a dedicated diagnostic product development effort, coordinated by the Foundation for Innovative New Diagnostics (FIND) and based on collaborations with key diagnostic partners, which would work under the auspice of the Coalition for Epidemics and Preparedness Innovations (CEPI) 16,17 with the specific goal of ensuring that diagnostic outbreak needs are comprehensively addressed. Such a partnering model between CEPI, FIND, and other key diagnostics players such as Institut Pasteur (CEPIdx) would need to have a unified vision for achieving diagnostic preparedness and response.…”

Post-Ebola reforms: ample analysis, inadequate action

“…India is finalising its contribution, and the European Commission plans to cofund projects with CEPI. 31 In early 2016 the Gavi Alliance announced a $5m payment to Merck to ensure adequate production of the rVSV vaccine in case of a resurgence of Ebola. 32 Beyond vaccines, funding shortages remain for research into drugs, diagnostics, and other health technologies, such as personal protective equipment.…”